ClinicalTrials.gg
TerminatedNCT02258529Updated May 14, 2019Results posted

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

A Phase 2 interventional study of Idelalisib and Rituximab in Follicular Lymphoma and Small Lymphocytic Lymphoma, sponsored by Gilead Sciences. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-14.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing idelalisib in Lymphoma, Follicular — none open to participants now, none under way, none of them phase 3. idelalisib · Lymphoma, Follicular.

Enrollment
9th of 12
10 · median 18
Started
2015
with 1 other
Phase 2
5 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
7 of 12
Gilead Sciences

Among the 12 studies testing idelalisib in Lymphoma, Follicular, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is one of 5 in phase 2, and was the 7th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

None of the 12 studies testing idelalisib in Lymphoma, Follicular is open now. The open studies under Lymphoma, Follicular, anywhere →

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing idelalisib in Lymphoma, Follicular as a file.
02

Study summary

The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL).

An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.

03

Conditions studied

  • Follicular Lymphoma
  • Small Lymphocytic Lymphoma

Keywords

  • Cancer
  • Indolent Non-Hodgkin Lymphoma
  • FL
  • SLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • confirmed diagnosis of B-cell lymphoma
  • No previous systemic treatment for lymphoma
  • Subject demonstrates need for treatment for lymphoma
  • Ann-Arbor Stage 2 (noncontiguous), 3, or 4 disease
  • Radiographically measurable lymphadenopathy or extranodal lymphoid
  • Adequate performance status
  • Required baseline laboratory data within protocol-specified parameters

Key Exclusion Criteria:

  • Known history of transformed lymphoma or diffuse large cell lymphoid malignancy
  • Known history of, or clinically apparent, central nervous system (CNS) lymphoma or lymphoma
  • Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
  • Known history of drug-induced liver injury, chronic active (HBV), chronic active (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
  • Ongoing inflammatory bowel disease
  • Known (HIV) infection
  • History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
  • Ongoing therapy, including systemic (> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for anemia and/or thrombocytopenia

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Idelalisib + rituximab

    Idelalisib + rituximab for up to 104 weeks

    Drug: Idelalisib · Biological: Rituximab

Interventions

  • 150 tablets administered orally twice daily

    Also known as: Zydelig®, GS-1101

  • BiologicalRituximab

    375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)

    Also known as: Rituxan®, MabThera®

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response during idelalisib treatment. ORR was to be assessed by an independent review committee (IRC).

Secondary outcomes

  1. Overall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AEs), Severe AEs (SAEs), AEs Leading to Idelalisib (IDL) Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death

    Time frame: Up to 24 weeks plus 30 days

  2. Rate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings

    The rate of Grade ≥ 3 transaminase elevations was defined as the number of participants with any Grade 3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations.

    Time frame: Up to 24 weeks plus 30 days

  3. Idelalisib Trough and Peak Plasma Concentrations

    Time frame: Predose and 1.5 hour postdose at Weeks 2, 4, and 12

  4. Time to Response

    Time to response was defined as the the interval from the start of idelalisib treatment to the first documentation of complete or partial response.

  5. Duration of Response

    Duration of response (DOR) was defined as the interval from the first documentation of complete response or partial response to the earlier of the first documentation of disease progression or death from any cause.

  6. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.

  7. Overall Survival

    Overall survival was defined as the interval from enrollment to death from any cause.

  8. Changes in Health-Related Quality of Life

    Changes in health-related quality of life was to be reported by participants using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire.

07

Results

Posted May 18, 2017
Limitations and caveats
Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 14 September 2015. The last study visit occurred on 03 May 2016.

Participant flow — Overall Study
MilestoneIdelalisib + Rituximab
Started10
Completed0
Not completed10
Withdrew: Study terminated by sponsor9
Withdrew: Adverse event1

Outcome measures

PrimaryOverall Response Rate

Overall response rate (ORR) was defined as the proportion of participants who achieve a confirmed complete or partial response during idelalisib treatment. ORR was to be assessed by an independent review committee (IRC).

No measurements were reported for this outcome.

SecondaryOverall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AEs), Severe AEs (SAEs), AEs Leading to Idelalisib (IDL) Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death
Time frame:
Up to 24 weeks plus 30 days
Reported as:
Number · percentage of participants
Overall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AEs), Severe AEs (SAEs), AEs Leading to Idelalisib (IDL) Interruption, Idelalisib Dose Reduction, Premature Discontinuation of Idelalisib, or Death
percentage of participantsIdelalisib + Rituximab
Any AE90.0
Any SAEs30.0
Any AE Leading to Idelalisib Interruption60.0
Any AE Leading to Idelalisib Dose Reduction30.0
Any AE Leading to Premature Discontinuation of IDL10.0
Any AE Leading to Death0
SecondaryRate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings

The rate of Grade ≥ 3 transaminase elevations was defined as the number of participants with any Grade 3 or 4 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations.

Time frame:
Up to 24 weeks plus 30 days
Reported as:
Number · percentage of participants
Rate of Grade ≥ 3 Transaminase Elevations Based on Laboratory Findings
percentage of participantsIdelalisib + Rituximab
Any Grade 3 or 4 ALT Elevation40.0
Any Grade 3 or 4 AST Elevation10.0
SecondaryIdelalisib Trough and Peak Plasma Concentrations
Time frame:
Predose and 1.5 hour postdose at Weeks 2, 4, and 12
Reported as:
Mean · ng/mL
Idelalisib Trough and Peak Plasma Concentrations
ng/mLIdelalisib + Rituximab
Week 2 predose216.2 ± 161.73
Week 2 1.5 hours postdose2240.0 ± 880.03
Week 4 predose347.4 ± 365.57
Week 4 1.5 hours postdose2084.3 ± 1346.26
Week 12 predose290.5 ± 373.08
Week 12 1.5 hours postdose1313.1 ± 1474.87
SecondaryTime to Response

Time to response was defined as the the interval from the start of idelalisib treatment to the first documentation of complete or partial response.

No measurements were reported for this outcome.

SecondaryDuration of Response

Duration of response (DOR) was defined as the interval from the first documentation of complete response or partial response to the earlier of the first documentation of disease progression or death from any cause.

No measurements were reported for this outcome.

SecondaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from the start of idelalisib treatment to the earlier of the first documentation of disease progression or death from any cause.

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the interval from enrollment to death from any cause.

No measurements were reported for this outcome.

SecondaryChanges in Health-Related Quality of Life

Changes in health-related quality of life was to be reported by participants using the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) questionnaire.

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to the last dose date plus 30 days (maximum: 24.1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib + Rituximab0/10 (0%)3/10 (30%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventIdelalisib + Rituximab
Oedema peripheralGeneral disorders1/10
SepsisInfections and infestations1/10
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/10
Trigeminal neuralgiaNervous system disorders1/10
PneumonitisRespiratory, thoracic and mediastinal disorders1/10
Most frequent other events
Showing 10 of 80
Most frequent other events
EventIdelalisib + Rituximab
Alanine aminotransferase increasedInvestigations5/10
Aspartate aminotransferase increasedInvestigations5/10
Infusion related reactionInjury, poisoning and procedural complications4/10
NeutropeniaBlood and lymphatic system disorders3/10
DiarrhoeaGastrointestinal disorders3/10
VomitingGastrointestinal disorders3/10
FatigueGeneral disorders3/10
Acute kidney injuryRenal and urinary disorders3/10
RashSkin and subcutaneous tissue disorders3/10
Rash maculo-papularSkin and subcutaneous tissue disorders3/10

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set: all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Idelalisib + Rituximab
Mean69 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib + Rituximab
Female6
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Idelalisib + Rituximab
Hispanic or Latino0
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Idelalisib + Rituximab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White10
More than one race0
Unknown or Not Reported0
08

Study locations

6 sites
  • Pacific Shores Medical Group
    Long Beach, California 90813, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Prarie Lakes Health Care Systems, Inc.
    Watertown, South Dakota 57201, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
09

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Apr 2016, 6 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2014
First posted
Oct 7, 2014
StartActual
Sep 14, 2015
Primary completionActual
Apr 12, 2016
CompletionActual
May 3, 2016
Results first posted
May 18, 2017
Last update
May 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02258529
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 7, 2014
Start date
Sep 14, 2015
Primary completion
Apr 12, 2016
Completion
May 3, 2016
Results posted
May 18, 2017
Last update
May 14, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Idelalisib · Rituximab

Start the discussion